Effects of Melatonin Supplementation on Clinical Symptoms and Paraclinical Outcomes in Women Diagnosed With Fibrocystic Breast Disease: An Interventional Study
Abstract
Fibrocystic breast disease is the most common benign breast disease in women, and it is necessary to investigate the most effective treatment method to reduce its symptoms. Therefore, the study was conducted to investigate the effect of melatonin supplementation on clinical symptoms and paraclinical outcomes in women diagnosed with fibrocystic breast disease. Investigating the Effects of melatonin supplementation on clinical symptoms and paraclinical outcomes in women diagnosed with fibrocystic breast disease. The present study is a controlled intervention-placebo treatment conducted on women suffering from fibrocystic breast disease aged 18-40. This interventional study was conducted on 66 patients (33 in the intervention group and 33 in the control group). Melatonin supplement of 3 mg was administered to the intervention group and a placebo to the control group for 12 weeks. Patient information, symptoms, and paraclinical outcomes were recorded at the beginning of the study before the intervention and 12 weeks after the intervention. After collecting the data, we analyzed it using SPSS version 16 software and appropriate statistical tests. The findings of this study showed that melatonin administration in patients with fibrocystic breast disease reduced anxiety, depression, improved sleep quality, increased TAC (Total Antioxidant Capacity), and decreased MDA (Malondialdehyde). However, both study groups did not have statistically significant differences in the average pain and hs-CRP before and after the intervention. According to the findings of the study and the identification of the positive effect of melatonin on laboratory indicators and symptoms in patients with fibrocystic breast disease, it is recommended to prescribe melatonin in addition to standard treatment to witness a better and faster recovery, and in this way, the quality of life of patients can be increased.
2. Brkic M, Vujovic S, Ivanisevic MF, Ivovic M, Gajic MT, Marina L, et al. The influence of progesterone gel therapy in the treatment of fibrocystic breast disease. Open Journal of Obstetrics and Gynecology. 2016;6(5):334-41.
3. Kunicki M, Smolarczyk R. Polycystic ovary syndrome and fibrocystic breast disease: an updated review. Hormone and Metabolic Research. 2021;53(04):219-24.
4. Laitman Y, Feldman DM, Sklair-Levy M, Yosepovich A, Barshack-Nakar I, Brodsky M, et al. Abnormal findings detected by multi-modality breast imaging and biopsy results in a high-risk clinic. Clinical Breast Cancer. 2018;18(4):e695-e8.
5. Irgebay Z, Yeszhan B, Sen B, Tuleukhanov S, Brooks AD, Sensenig R, et al. Danazol alters mitochondria metabolism of fibrocystic breast Mcf10A cells. The Breast. 2017;35:55-62.
6. Dong C, Zhang L, Sun R, Liu J, Yin H, Li X, et al. Role of thioredoxin reductase 1 in dysplastic transformation of human breast epithelial cells triggered by chronic oxidative stress. Scientific reports. 2016;6(1):1-13.
7. Kour A, Sharma S, Sambyal V, Guleria K, Singh NR, Uppal MS, et al. Risk factor analysis for breast cancer in premenopausal and postmenopausal women of Punjab, India. Asian Pacific Journal of Cancer Prevention: APJCP. 2019;20(11):3299.
8. Rosa M, Agosto-Arroyo E. Core needle biopsy of benign, borderline and in-situ problematic lesions of the breast: Diagnosis, differential diagnosis and immunohistochemistry. Annals of diagnostic pathology. 2019;43:151407.
9. Mullooly M, Nyante SJ, Pfeiffer RM, Cora R, Butcher D, Sternberg L, et al. Involution of breast lobules, mammographic breast density and prognosis among tamoxifen-treated estrogen receptor-positive breast cancer patients. Journal of Clinical Medicine. 2019;8(11):1868.
10. Li Y, Tang Y, Qiu C, Lin Q, Xie C, Zhou M, et al. Analysis of common gynecological diseases in 1142 married female workers. Zhonghua lao Dong wei Sheng zhi ye Bing za zhi= Zhonghua Laodong Weisheng Zhiyebing Zazhi= Chinese Journal of Industrial Hygiene and Occupational Diseases. 2019;37(10):785-8.
11. Murshid KR. A review of mastalgia in patients with fibrocystic breast changes and the non-surgical treatment options. Journal of Taibah University Medical Sciences. 2011;6(1):1-18.
12. Nabi Foodani M, Mohamadnejad Ostad F, Navab E, Bahrampouri S, Abbasi Dolatabadi Z. Self-care and Standard Precaution Observance in intensive care nurses during COVID 19. Health Education and Health Promotion. 2023;11(1):3-10.
13. Kakaei S, Zakerimoghadam M, Rahmanian M, Dolatabadi ZA. The impact of climate change on heart failure: a narrative review study. Shiraz E-Medical Journal. 2021;22(9).
14. Kanat BH, Atmaca M, Girgin M, Ilhan YS, Bozdağ A, Özkan Z, et al. Effects of mastalgia in young women on quality of life, depression, and anxiety levels. Indian Journal of Surgery. 2016;78:96-9.
15. Ahiskalioglu A, Yayik AM, Demir U, Ahiskalioglu EO, Celik EC, Ekinci M, et al. Preemptive analgesic efficacy of the ultrasound-guided bilateral superficial serratus plane block on postoperative pain in breast reduction surgery: a prospective randomized controlled study. Aesthetic Plastic Surgery. 2020;44:37-44.
16. Mahmodabadi AZ, Zakerimoghadam M, Fatah SG, Sohrabi A, Dolatabadi ZA. Nursing empowerment by simulation in percutaneous endoscopic gastrostomy short-time complication control: Protocol study. Journal of Education and Health Promotion. 2020;9.
17. Haynes BP, Ginsburg O, Gao Q, Folkerd E, Afentakis M, Buus R, et al. Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer. NPJ breast cancer. 2019;5(1):42.
18. Banuelos J, Sabbagh MD, Roh S-G, Nguyen M-DT, Lemaine V, Tran NV, et al. Infections following immediate implant-based breast reconstruction: a case-control study over 11 years. Plastic and reconstructive surgery. 2019;144(6):1270-7.
19. Fu L, Sun X, Lyu H, Shui R, Xu X, Yang W. Low grade adenosquamous carcinoma arising from sclerosing adenosis of the breast: report of a case. Zhonghua bing li xue za zhi= Chinese journal of pathology. 2019;48(5):415-7.
20. Bhattacharya S, Patel KK, Dehari D, Agrawal AK, Singh S. Melatonin and its ubiquitous anticancer effects. Molecular and cellular biochemistry. 2019;462:133-55.
21. Kong X, Gao R, Wang Z, Wang X, Fang Y, Gao J, et al. Melatonin: a potential therapeutic option for breast cancer. Trends in Endocrinology & Metabolism. 2020;31(11):859-71.
22. Mirhashemi SM, Najafi V, Raygan F, Asemi Z. The effects of coenzyme Q10 supplementation on cardiometabolic markers in overweight type 2 diabetic patients with stable myocardial infarction: A randomized, double-blind, placebo-controlled trial. ARYA atherosclerosis. 2016;12(4):158.
23. Raygan F, Ostadmohammadi V, Bahmani F, Reiter RJ, Asemi Z. Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: a randomized, double-blind, placebo-controlled trial. Clinical Nutrition. 2019;38(1):191-6.
24. Alamdari NM, Mahdavi R, Roshanravan N, Yaghin NL, Ostadrahimi A, Faramarzi E. A double-blind, placebo-controlled trial related to the effects of melatonin on oxidative stress and inflammatory parameters of obese women. Hormone and Metabolic Research. 2015;47(07):504-8.
25. Koziróg M, Poliwczak AR, Duchnowicz P, Koter‐Michalak M, Sikora J, Broncel M. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. Journal of pineal research. 2011;50(3):261-6.
26. Sohaei S, Amani R, Tarrahi MJ, Ghasemi-Tehrani H. The effects of curcumin supplementation on glycemic status, lipid profile and hs-CRP levels in overweight/obese women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled clinical trial. Complementary therapies in medicine. 2019;47:102201.
27. Hawker GA, Mian S, Kendzerska T, French M. Measures of adult pain: Visual analog scale for pain (vas pain), numeric rating scale for pain (nrs pain), mcgill pain questionnaire (mpq), short‐form mcgill pain questionnaire (sf‐mpq), chronic pain grade scale (cpgs), short form‐36 bodily pain scale (sf‐36 bps), and measure of intermittent and constant osteoarthritis pain (icoap). Arthritis care & research. 2011;63(S11):S240-S52.
28. Fadaeizadeh L, Emami H, Samiei K. Comparison of visual analogue scale and faces rating scale in measuring acute postoperative pain. 2009.
29. Wang Y-P, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Brazilian Journal of Psychiatry. 2013;35:416-31.
30. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. Journal of consulting and clinical psychology. 1988;56(6):893.
31. Buysse DJ, Reynolds III CF, Monk TH, Hoch CC, Yeager AL, Kupfer DJ. Quantification of subjective sleep quality in healthy elderly men and women using the Pittsburgh Sleep Quality Index (PSQI). Sleep. 1991;14(4):331-8.
32. Chehri A, Nourozi M, Eskandari S, Khazaie H, Hemati N, Jalali A. Validation of the Persian version of the Pittsburgh Sleep Quality Index in elderly population. Sleep Science. 2020;13(2):119.
33. Kaviani H, Mousavi A. Psychometric properties of the Persian version of Beck Anxiety Inventory (BAI). Tehran University Medical Journal. 2008.
34. Adamczyk-Sowa M, Pierzchala K, Sowa P, Polaniak R, Kukla M, Hartel M. Influence of melatonin supplementation on serum antioxidative properties and impact of the quality of life in multiple sclerosis patients. J Physiol Pharmacol. 2014;65(4):543-50.
Files | ||
Issue | Vol 61 No 11 (2023) | |
Section | Articles | |
DOI | https://doi.org/10.18502/acta.v61i11.16081 | |
Keywords | ||
Fibrocystic breast disease Melatonin Anxiety disorders Pain Depression Sleep quality |
Rights and permissions | |
![]() |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |